{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:36:21Z","timestamp":1792136181935,"version":"4.4.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Vaccines, Inc., Boston, MA, USA"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-na\u00efve individuals. This phase 3 study assessed the immunogenicity and safety of concomitant and sequential administration of YF (YF-17D) and tetravalent dengue (TAK-003) vaccines in healthy adults aged 18\u201360 years living in areas of the US non-endemic for either virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were randomized 1:1:1 to receive the following vaccinations at Months 0, 3, and 6, respectively: YF-17D+placebo, TAK-003, and TAK-003 (Group 1); TAK-003+placebo, TAK-003, and YF-17D (Group 2); or YF-17D+TAK-003, TAK-003, and placebo (Group 3). The primary objective was to demonstrate non-inferiority (upper bound of 95% confidence interval [UB95%CI] of difference &lt;5%) of YF seroprotection rate one month following concomitant administration of YF-17D and TAK-003 (Group 3) compared with YF-17D plus placebo (Group 1). The secondary objectives included demonstration of non-inferiority of YF and dengue geometric mean titers (GMTs) (UB95%CI for GMT ratio &lt;2.0), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>900 adults were randomized. YF seroprotection rates one month post-YF-17D (Month 1) were 99.5% and 99.1% in Group 1 and 3, respectively, and non-inferiority was demonstrated (UB95%CI = 2.69% i.e. &lt;5%). Non-inferiority was also demonstrated for GMTs against YF one month post-YF-17D, and against DENV-2, -3, and -4 (UB95%CI &lt;2), but not DENV-1 (UB95%CI: 2.22), one month post-second TAK-003 vaccination. Adverse event rates following TAK-003 were consistent with previous results, and no important safety risks were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, YF-17D vaccine and TAK-003 were immunogenic and well tolerated when sequentially or concomitantly administered. The non-inferiority of immune responses to YF-17D and TAK-003 was demonstrated for concomitant administration of the 2 vaccines compared to separate vaccination, except against DENV-1 but with GMTs similar to those observed in other TAK-003 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identified:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03342898\" xlink:type=\"simple\">NCT03342898<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0011124","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T13:44:59Z","timestamp":1678283099000},"page":"e0011124","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-8647","authenticated-orcid":true,"given":"Vianney","family":"Tricou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"pntd.0011124.ref001","author":"World Health Organization","year":"2020","journal-title":"Ten threats to global health in 2019"},{"issue":"7446","key":"pntd.0011124.ref002","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"S Bhatt","year":"2013","journal-title":"Nature"},{"issue":"9","key":"pntd.0011124.ref003","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"JP Messina","year":"2019","journal-title":"Nature Microbiology"},{"issue":"8","key":"pntd.0011124.ref004","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"DS Shepard","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011124.ref005","author":"World Health Organization","journal-title":"Yellow fever fact sheet 2019"},{"key":"pntd.0011124.ref006","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-308X(05)62006-4","article-title":"The global distribution of yellow fever and dengue.","volume":"62","author":"DJ Rogers","year":"2006","journal-title":"Adv Parasitol"},{"issue":"4","key":"pntd.0011124.ref007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: the recurring plague","volume":"41","author":"O. Tomori","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"pntd.0011124.ref008","first-page":"77","article-title":"The yellow fever vaccine: a history","volume":"83","author":"JG Frierson","year":"2010","journal-title":"Yale J Biol Med"},{"issue":"3","key":"pntd.0011124.ref009","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"E Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0011124.ref010","doi-asserted-by":"crossref","first-page":"e0149871","DOI":"10.1371\/journal.pone.0149871","article-title":"A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination","volume":"11","author":"RW Wieten","year":"2016","journal-title":"PLoS One"},{"key":"pntd.0011124.ref011","volume-title":"International Health Regulations","author":"World Health Organization","year":"2005","edition":"3"},{"issue":"5","key":"pntd.0011124.ref012","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).","volume":"7","author":"CY Huang","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"pntd.0011124.ref013","article-title":"editor Dengue virus vaccine development: study on biological markers of uncloned dengue 1\u20134 viruses serially passaged in primary kidney cells","author":"BN Yoksan S","year":"1986","journal-title":"Arbovirus research in Australia: Proceedings of the 4th Symposium Brisbane, Australia: Commonwealth Scientific and Industrial Research Organization, Division of Tropical Animal Science and Queensland Institute of Medical Research"},{"issue":"42","key":"pntd.0011124.ref014","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"JE Osorio","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0011124.ref015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.","volume":"15","author":"JE Osorio","year":"2016","journal-title":"Expert Rev Vaccines."},{"issue":"7","key":"pntd.0011124.ref016","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial","volume":"212","author":"SL George","year":"2015","journal-title":"J Infect Dis"},{"issue":"9","key":"pntd.0011124.ref017","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.","volume":"14","author":"JE Osorio","year":"2014","journal-title":"Lancet Infect Dis."},{"issue":"46","key":"pntd.0011124.ref018","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.","volume":"33","author":"R Rupp","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"pntd.0011124.ref019","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.","volume":"213","author":"C Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"pntd.0011124.ref020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial","volume":"38","author":"V Tricou","year":"2020","journal-title":"Vaccine"},{"issue":"10234","key":"pntd.0011124.ref021","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial.","volume":"395","author":"V Tricou","year":"2020","journal-title":"Lancet"},{"key":"pntd.0011124.ref022","first-page":"1","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.","author":"M Turner","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"21","key":"pntd.0011124.ref023","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"S Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"10234","key":"pntd.0011124.ref024","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"S Biswal","year":"2020","journal-title":"Lancet"},{"key":"pntd.0011124.ref025","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination.","author":"E L\u00f3pez-Medina","year":"2020","journal-title":"J Infect Dis"},{"key":"pntd.0011124.ref026","first-page":"ciab864","article-title":"Three years efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003).","author":"L Rivera","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pntd.0011124.ref027","author":"Centers for Disease Control and Prevention","year":"2020","journal-title":"Vaccine Recommendations and Guidelines of the ACIP. Timing and Spacing of Immunobiologics"},{"issue":"12","key":"pntd.0011124.ref028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1348-0421.1994.tb02152.x","article-title":"Studies on serological cross-reaction in sequential flavivirus infections","volume":"38","author":"Y Makino","year":"1994","journal-title":"Microbiol Immunol"},{"issue":"1","key":"pntd.0011124.ref029","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12879-018-3389-x","article-title":"Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults","volume":"18","author":"J Kirstein","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"10","key":"pntd.0011124.ref030","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12\u201313 Months of Age in Colombia and Peru: A Randomized Trial.","volume":"35","author":"P L\u00f3pez","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pntd.0011124.ref031","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.","volume":"2","author":"F Guirakhoo","year":"2006","journal-title":"Hum Vaccin."},{"issue":"6 Suppl","key":"pntd.0011124.ref032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4269\/ajtmh.2003.69.32","article-title":"Atypical antibody responses in dengue vaccine recipients","volume":"69","author":"N Kanesa-Thasan","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0011124.ref033","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-019-0133-5","article-title":"Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination","volume":"4","author":"V Bradt","year":"2019","journal-title":"npj Vaccines"},{"issue":"37","key":"pntd.0011124.ref034","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"JR Nascimento Silva","year":"2011","journal-title":"Vaccine"},{"key":"pntd.0011124.ref035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"22","key":"pntd.0011124.ref036","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C","article-title":"Improved confidence intervals for the difference between binomial proportions based on paired data.","volume":"17","author":"RG Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"Pt 12","key":"pntd.0011124.ref037","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1099\/vir.0.031641-0","article-title":"Flavivirus-induced antibody cross-reactivity","volume":"92","author":"KL Mansfield","year":"2011","journal-title":"J Gen Virol"},{"key":"pntd.0011124.ref038","doi-asserted-by":"crossref","first-page":"e190098","DOI":"10.1590\/0074-02760190098","article-title":"Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses","volume":"114","author":"RA Oliveira","year":"2019","journal-title":"Mem Inst Oswaldo Cruz"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T13:45:35Z","timestamp":1678283135000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011124"}},"subtitle":[],"editor":[{"given":"Hannah E.","family":"Clapham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011124","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}